Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models

The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle/bone tissue

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Endocrine Disorders Acromegaly Adiposity Adrenal Gland Diseases Adrenocortical Hyperfunction Body Weight Bone Diseases Bone Diseases, Endocrine Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Cushing Syndrome Endocrine Gland Neoplasms Endocrine System Diseases Hyperpituitarism Hypopituitarism Hypothalamic Diseases Hypothalamic Neoplasms Musculoskeletal Diseases Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pituitary Adenoma Pituitary Diseases Pituitary Neoplasms Signs and Symptoms Supratentorial Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Obese patients affected and not by hypothalamic-pituitary diseases

Exclusion criteria

Minor subjects;
Pregnant and/or breastfeeding women;
Patients suffering from states of primary and/or acquired immunodeficiencies, and/or serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening/reacerbated/compensated chronic pathologies);
Patients unable to understand and sign the Informed Consent.

Treatment and study plan

Primary outcomes

Rate of patients with BMI greater than 30 with hypothalamic-pituitary pathologies

Time frame: retrospective and prospective collection of clinical data between 01/01/2021 and 31/12/2026

The study aims to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2026
First posted: Mar 22, 2024
Registry last updated: Jun 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting